Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El estudio INITIATE: Inicio del tratamiento de la dependencia de la nicotina para fumadores ingresados ​​en los departamentos de emergencia (INITIATE)

30 de octubre de 2026 actualizado por: Ottawa Heart Institute Research Corporation

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1208

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Evyanne Wooding, R.Kin
  • Número de teléfono: 17596 613-696-7000
  • Correo electrónico: ewooding@ottawaheart.ca

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Ontario
      • Ottawa, Ontario, Canadá
        • Reclutamiento
        • University of Ottawa Heart Institute
        • Contacto:
          • Dr. Kerri-Anne Mullen
          • Número de teléfono: 613-696-7000 ext.19095
          • Correo electrónico: KMullen@ottawaheart.ca
      • Ottawa, Ontario, Canadá
        • Reclutamiento
        • Civic Hospital
        • Contacto:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Número de teléfono: 6137985555,17023
          • Correo electrónico: vthirug@toh.ca
      • Ottawa, Ontario, Canadá
        • Reclutamiento
        • General Hospital
        • Contacto:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Número de teléfono: 6137985555,17023
          • Correo electrónico: vthirug@toh.ca
      • Ottawa, Ontario, Canadá
        • Reclutamiento
        • Riverside Hospital
        • Contacto:
          • Dr. Venkatesh Thiruganasambandamoorthy
          • Número de teléfono: 6137985555,17023
          • Correo electrónico: vthirug@toh.ca

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Current daily smoker (smokes ≥ 5 cigarettes per day);
  • ≥ 18 years of age (the age of majority in Ontario);
  • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
  • Able to read and understand English or French;
  • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  • Available and willing to participate in follow-up assessments over the next 12 months;
  • Has access to a telephone or computer;
  • Able to provide informed consent

Exclusion Criteria:

  • Currently participating in this or another smoking cessation study;
  • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
  • Pregnant, planning to become pregnant over the next year, or breastfeeding;
  • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
  • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
  • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Quit Card Intervention (QCI)

Study intervention group.

The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.

Sin intervención: Usual Care (UC)

Study control group.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Smoking Abstinence
Periodo de tiempo: 26 weeks (6 months) after study enrollment

Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test

26 weeks (6 months) after study enrollment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Prolonged Abstinence
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Point Prevalence Abstinence
Periodo de tiempo: 4, and 52 weeks after study enrollment

Point prevalence smoking abstinence, at 4, and 52 weeks

4, and 52 weeks after study enrollment
Smoking Reduction
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Number of Quit Attempts
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Number of quit attempts since study entry, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cessation Medication and/or E-cigarette Use
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Use of Behavioural Supports
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health-Related Quality of Life
Periodo de tiempo: 52 weeks after study enrollment

Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

52 weeks after study enrollment
Health Services Outcomes - ED visits
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Hospital Admissions
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Health Services Outcomes - Deaths
Periodo de tiempo: 4, 26, and 52 weeks after study enrollment

Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks

4, 26, and 52 weeks after study enrollment
Cost-Effectiveness Ratios
Periodo de tiempo: 52 weeks after study enrollment

Cost-effectiveness ratios related to health services at 52 weeks

52 weeks after study enrollment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de abril de 2022

Finalización primaria (Estimado)

1 de septiembre de 2027

Finalización del estudio (Estimado)

1 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

7 de octubre de 2019

Primero enviado que cumplió con los criterios de control de calidad

13 de noviembre de 2019

Publicado por primera vez (Actual)

14 de noviembre de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir